IGC Pharma, Inc. - IGC STOCK NEWS

India Globalization Capital, Inc. (IGC) reported impressive third fiscal quarter 2023 results, with net revenue soaring 133% to $332,000 year-over-year, driven by its life science segment. The company is advancing its Phase 2 clinical trial for IGC-AD1, targeting agitation in dementia due to Alzheimer’s, expanding sites from four to up to 12 to enhance enrollment. The trial aims to involve 146 patients and establish efficacy over six weeks. R&D expenses rose to $806,000 due to increased trial activities, while SG&A expenses decreased to $1.5 million. Despite a net loss of $2.2 million, IGC remains optimistic about expanding its market presence and future FDA approval.

India Globalization Capital (NYSE American: IGC) announces an upcoming investor webinar featuring CEO Ram Mukunda and PFO Claudia Grimaldi on February 10, 2023, at 12:30 p.m. ET. They will discuss the Company’s Phase 2 trial for IGC-AD1, aimed at alleviating agitation in Alzheimer's patients. The trial involves 146 participants and is categorized as Phase 2B for safety and efficacy. IGC is focused on developing cannabinoid-based formulations for various conditions, including Alzheimer’s disease. The Company also markets wellness brands Holief and Sunday Seltzer.

India Globalization Capital (IGC) announced a no objection letter from Health Canada for its Phase 2 trial of IGC-AD1, targeting agitation in Alzheimer's disease. This approval allows the company to proceed with trials at multiple sites, including Canada and the U.S. CEO Ram Mukunda emphasized the importance of this milestone for patient enrollment and FDA approval. The formulation utilizes low doses of THC and has shown promise in early trials. Approximately 15 million people in North America and Europe are affected by Alzheimer's, highlighting the potential market impact.

India Globalization Capital, Inc. (IGC) has filed a life sciences presentation with the SEC on Form 8K, detailing its initiatives, particularly focusing on low-dose THC drug formulations and cannabinoid-based consumer products.

IGC's leading drug candidate, IGC-AD1, is in Phase 2 trials, targeting agitation in Alzheimer’s dementia. The company also offers CBD products for various health needs. Despite these advancements, the press release includes forward-looking statements subject to risks, such as regulatory challenges and market conditions that could impact product commercialization.

India Globalization Capital, Inc. (NYSE: IGC) has expressed strong support for the Medical Marijuana and Cannabidiol Research Expansion Act, signed into law by President Biden on December 2, 2022. This Act aims to streamline research on marijuana and enhance product availability for medical applications. CEO Ram Mukunda noted that this development is crucial for advancing cannabis research. The company's IGC-AD1 is currently undergoing a Phase 2 clinical trial for Alzheimer’s-related agitation, following promising Phase 1 results showing potential benefits in managing Aβ plaques.

India Globalization Capital, Inc. (IGC) has initiated a Phase 2 clinical trial for IGC-AD1, aimed at treating agitation in Alzheimer's patients. The multi-center, double-blind study will enroll 146 participants, with the aim of assessing the treatment's safety and efficacy. The trial will take place across multiple sites in the U.S., Canada, and potentially South America, targeting diverse populations. IGC-AD1 is notable for being the first low-dose natural THC-based formulation in FDA trials for this condition. The trial's findings could provide insights into treating a condition affecting millions globally.

India Globalization Capital (NYSE American: IGC) announced that CEO Ram Mukunda will present at the RHK Disruptive Growth Conference in New York City on December 5 at 11:20 am ET. One-on-one meetings are scheduled for December 5 and 6. IGC focuses on developing cannabinoid-based formulations for treating diseases, including Alzheimer's and Parkinson's, with its leading candidate IGC-AD1 recently entering Phase 2 clinical trials. The company also offers CBD-based consumer products like Holief and Sunday Seltzer, catering to various health needs.

India Globalization Capital (NYSE American: IGC) announced its second fiscal quarter 2023 financial results, highlighting significant progress in its investigational drugs for Alzheimer’s. IGC-AD1 is entering Phase 2 trials aimed at treating agitation in Alzheimer’s dementia, with a primary endpoint assessed over six weeks. The company's revenue surged to approximately $202,000, up from $56,000 a year earlier, largely due to increased sales of CBD products. SG&A expenses dropped to $1.9 million, while R&D expenses rose to $768,000, reflecting ongoing trials. The net loss decreased to $2.4 million or ($0.05) per share.

India Globalization Capital (IGC) announced that the USPTO has granted a second patent (#11,446,276) for treating Alzheimer’s disease with extreme low dose THC. The original application was initiated by the University of South Florida in 2015, and IGC has developed IGC-AD1 based on this research. Early testing indicates IGC-AD1 may alleviate key Alzheimer’s symptoms, prompting a Phase 2 protocol filing with the FDA for further efficacy testing. Currently, no pharmacological treatments for agitation in Alzheimer’s patients exist, presenting a significant market opportunity for IGC.